The innate immune system in demyelinating disease

Immunological Reviews

Volumn 248, Issue 1, 2012, Pages 170-187

  Mayo, Lior ^a   Quintana, Francisco J ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Astrocyte; Central nervous system; Demyelination; Innate immunity; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CYPROHEPTADINE; NATALIZUMAB; PROXICROMIL; RESERPINE;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; ASTROCYTE; B LYMPHOCYTE; DEMYELINATING DISEASE; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; HUMAN; INNATE IMMUNITY; MAST CELL; MICROGLIA; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; ANIMALS; ASTROCYTES; B-LYMPHOCYTES; BLOOD-BRAIN BARRIER; DEMYELINATING DISEASES; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MAST CELLS; MONONUCLEAR PHAGOCYTE SYSTEM; T-LYMPHOCYTE SUBSETS;

EID: 84862736732     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01135.x     Document Type: Article

References (224)

1. Doring A, Yong VW. The good, the bad and the ugly. Macrophages/microglia with a focus on myelin repair. Front Biosci 2011;3:846-856.
2. Hanafy KA, Sloane JA. Regulation of remyelination in multiple sclerosis. FEBS Lett 2011;585:3821-3828.
3. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255(Suppl.):3-11.
4. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004;61:1613-1615.
5. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-248.
6. Wender M. Acute disseminated encephalomyelitis (ADEM). J Neuroimmunol 2011;231:92-99.
7. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006;33:270-298.
8. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011;18:21-29.
9. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-925.
10. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009;118:723-736.
11. Skripuletz T, Gudi V, Hackstette D, Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol 2011;26:1585-1597.
12. Kim BS, Palma JP, Kwon D, Fuller AC. Innate immune response induced by Theiler's murine encephalomyelitis virus infection. Immunol Res 2005;31:1-12.
13. Basso AS, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008;118:1532-1543.
14. Karni A, Koldzic DN, Bharanidharan P, Khoury SJ, Weiner HL. IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002;125:134-140.
15. Karni A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-4202.
16. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603.
17. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 2009;10:958-964.
18. Daneman R, Rescigno M. The gut immune barrier and the blood-brain barrier: are they so different? Immunity 2009;31:722-735.
19. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 2011;585:3770-3780.
20. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
21. Frank BT, Rossall JC, Caughey GH, Fang KC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol 2001;166:2783-2792.
22. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011;1812:252-264.
23. Tchougounova E. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2004;280:9291-9296.
24. Johnson D, Seeldrayers PA, Weiner HL. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation. Brain Res 1988;444:195-198.
25. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000;191:813-822.
26. Modlin RL. Innate immunity: ignored for decades, but not forgotten. J Invest Dermatol 2011;132:882-886.
27. Sayed BA, Walker ME, Brown MA. Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis. J Immunol 2011;186:3294-3298.
28. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384.
29. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
30. Dimitriadou V, Pang X, Theoharides TC. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. Int J Immunopharmacol 2000;22:673-684.
31. Grahnert A, Grahnert A, Klein C, Schilling E, Wehrhahn J, Hauschildt S. Review: NAD+: a modulator of immune functions. Innate Immun 2011;17:212-233.
32. Dietsch GN, Hinrichs DJ. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. J Immunol 1989;142:1476-1481.
33. Penberthy WT, Tsunoda I. The importance of NAD in multiple sclerosis. Curr Pharm Des 2009;15:64-99.
34. Piconese S, et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009;114:2639-2648.
35. Andersson A, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008;84:1248-1255.
36. Forward NA, Furlong SJ, Yang Y, Lin T-J, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol 2009;183:3014-3022.
37. Quintana FJ, Farez MF, Izquierdo G, Lucas M, Cohen IR, Weiner HL. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 2012;78:532-539.
38. Quintana FJ, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008;105:18889-18894.
39. Walker ME, Hatfield JK, Brown MA. New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? Biochim Biophys Acta 2012;1822:57-65.
40. Tsan M-F, Gao B. Heat shock proteins and immune system. J Leukoc Biol 2009;85:905-910.
41. Gao H-M, Zhou H, Zhang F, Wilson BC, Kam W, Hong J-S. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011;31:1081-1092.
42. Ivanov S, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007;110:970-1981.
43. Thériault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK. Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett 2005;579:1951-1960.
44. Calderwood SK, Mambula SS, Gray PJ. Extracellular heat shock proteins in cell signaling and immunity. Ann NY Acad Sci 2007;1113:28-39.
45. Wesch D, Peters C, Oberg H-H, Pietschmann K, Kabelitz D. Modulation of γδ T cell responses by TLR ligands. Cell Mol Life Sci 2011;68:2357-2370.
46. Lünemann JD. Epstein-Barr virus in multiple sclerosis: a continuing conundrum. Neurology 2012;78:11-12.
47. Blink SE, Miller SD. The contribution of γδ T cells to the pathogenesis of EAE and MS. Curr Mol Med 2009;9:15-22.
48. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002;2:336-345.
49. Reboldi A, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-523.
50. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
51. Axtell RC, Steinman L. Gaining entry to an uninflamed brain. Nat Immunol 2009;10:453-455.
52. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27:119-145.
53. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011;91:461-553.
54. Shrivastava K, Gonzalez P, Acarin L. The immune inhibitory complex CD200/CD200R is developmentally regulated in the mouse brain. J Comp Neurol 2012; doi:
55. Hoek RM. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-1771.
56. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med 2011;17:64-70.
57. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron 2009;64:93-109.
58. Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010;28:813-815.
59. Wu L, Liu Y-J. Development of dendritic-cell lineages. Immunity 2007;26:741-750.
60. Wu H-Y, et al. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE 2011;6:e23618.
61. Quintana FJ, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71.
62. Severson C, Hafler DA. T-cells in multiple sclerosis. Results Probl Cell Differ 2010;51:75-98.
63. Barreira da Silva R, Münz C. Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals. Cell Mol Life Sci 2011;68:3505-3518.
64. Greter M, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334.
65. Miller SD, McMahon EJ, Schreiner B, Bailey SL. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann NY Acad Sci 2007;1103:179-191.
66. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005;11:335-339.
67. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008;181:7480-7488.
68. Murugaiyan G, Mittal A, Weiner HL. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci USA 2010;107:11495-11500.
69. Quintana FJ, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010;107:20768-20773.
70. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides "preferentially" polarize CD4+ TH-17 cells in relapsing EAE. Nat Immunol 2007;8:172-180.
71. Stasiolek M, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129:1293-1305.
72. Morandi B, et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008;57:1-5.
73. De Jager PL, et al. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008;131:1701-1711.
74. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127:1917-1927.
75. Lünemann A, et al. Human NK cells kill resting but not activated microglia via NKG2D-and NKp46-mediated recognition. J Immunol 2008;181:6170-6177.
76. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011;70:943-954.
77. Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000;165:3099-3104.
78. Matsumoto Y, et al. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 1998;28:1681-1688.
79. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi F-D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005;174:2696-2701.
80. Hammarberg H, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283-5291.
81. Bielekova B, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946.
82. Lünemann A, et al. Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis. Int Immunol 2011;23:139-148.
83. Takahashi K, et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001;107:R23-29.
84. Mayo L, Stein R. Characterization of LPS and interferon-gamma triggered activation-induced cell death in N9 and primary microglial cells: induction of the mitochondrial gateway by nitric oxide. Cell Death Differ 2007;14:183-186.
85. Ponomarev ED, Dittel BN. Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol 2005;174:4678-4687.
86. Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193-201.
87. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg M-L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 2010;30:689-702.
88. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FMV. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011;14:1142-1149.
89. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005;309:264-268.
90. Ibrahim MZ, Reder AT, Lawand R, Takash W, Sallouh-Khatib S. The mast cells of the multiple sclerosis brain. J Neuroimmunol 1996;70:131-138.
91. Ness-Schwickerath KJ, Morita CT. Regulation and function of IL-17A- and IL-22-producing γδ T cells. Cell Mol Life Sci 2011;68:2371-2390.
92. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1995;37:63-66.
93. Iarosh OO, Kanevs'ka SA. The characteristics of the blood histamine indices and of the pathomorphological changes in the gastric mucosa of patients with multiple sclerosis. Lik Sprava 1992;1:75-76.
94. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992;89:4588-4592.
95. Lock C, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508.
96. Kress E, Hedges JF, Jutila MA. Distinct gene expression in human Vdelta1 and Vdelta2 gammadelta T cells following non-TCR agonist stimulation. Mol Immunol 2006;43:2002-2011.
97. Shimonkevitz R, Colburn C, Burnham JA, Murray RS, Kotzin BL. Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. Proc Natl Acad Sci USA 1993;90:923-927.
98. Mix E, Olsson T, Correale J, Kostulas V, Link H. CD4+, CD8+, and CD4- CD8- T cells in CSF and blood of patients with multiple sclerosis and tension headache. Scand J Immunol 1990;31:493-501.
99. Stinissen P, et al. Increased frequency of gamma delta T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. J Immunol 1995;154:4883-4894.
100. Rinaldi L. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 2006;129:1993-2007.
101. Chen Z, Freedman MS. Correlation of specialized CD16+γδ T cells with disease course and severity in multiple sclerosis. J Neuroimmunol 2008;194:147-152.
102. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-142.
103. Podbielska M, Hogan E. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Multiple Sclerosis 2009;15:1011-1029.
104. Mars LT, et al. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008;181:2321-2329.
105. Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001;166:42-50.
106. Pál E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol 2001;166:662-668.
107. Mars LT, et al. Cutting edge: Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002;168:6007-6011.
108. Singh AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1801-1811.
109. O'Keeffe J, et al. T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. J Neurol Sci 2008;275:22-28.
110. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279-288.
111. Gausling R, Trollmo C, Hafler DA. Decreases in interleukin-4 secretion by invariant CD4-CD8-Vα24JαQ T cells in peripheral blood of patients with relapsing-remitting multiple sclerosis. Clin Immunol 2001;98:11-17.
112. Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007;122:409-417.
113. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010;221:7-14.
114. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-1318.
115. Davalos D. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752-758.
116. Anderson AC, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007;318:1141-1143.
117. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff R, Cardona A. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 2012;188:28-36.
118. Saederup N, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-Red fluorescent protein knock-in mice. PLoS ONE 2010;5:e13693.
119. Sato N, et al. Functional characterization of NK1.1+ Ly-6C+ cells. Immunol Lett 1996;54:5-9.
120. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009;113:5488-5496.
121. Prinz M, Priller J. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J Neuroimmunol 2010;224:80-84.
122. Horikoshi Y, et al. Human GLUT5 immunolabeling is useful for evaluating microglial status in neuropathological study using paraffin sections. Acta Neuropathol 2003;105:157-162.
123. Bédard A, Tremblay P, Chernomoretz A, Vallières L. Identification of genes preferentially expressed by microglia and upregulated during cuprizone-induced inflammation. Glia 2007;55:777-789.
124. Trebst C, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001;159:1701-1710.
125. Peterson JW, Bo L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
126. Moll NM, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology 2008;70:336-343.
127. Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
128. Satoh J-I, et al. Neuromyelitis optica/Devic's disease: gene expression profiling of brain lesions. Neuropathology 2008;28:561-576.
129. Bradl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
130. Heppner FL, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005;11:146-152.
131. Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD, Owens T. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 1998;161:3767-3775.
132. Huizinga R, et al. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012;60:422-431.
133. Bauer J, Sminia T, Wouterlood FG, Dijkstra CD. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 1994;38:365-375.
134. Katz-Levy Y, et al. Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice. J Immunol 2000;165:5304-5314.
135. Mildner A, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009;132:2487-2500.
136. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000;192:899-905.
137. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009;113:3190-3197.
138. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000;192:1075-1080.
139. Kotter MR, Zhao C, van Rooijen N, Franklin RJM. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005;18:166-175.
140. Kotter MR, Setzu A, Sim FJ, van Rooijen N, Franklin RJ. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001;35:204-212.
141. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75-85.
142. Magnus T, et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 2005;25:2537-2546.
143. Duncan DS, Miller SD. CNS expression of B7-H1 regulates pro-inflammatory cytokine production and alters severity of Theiler's virus-induced demyelinating disease. PLoS ONE 2011;6:e18548.
144. Kimelberg HK. Functions of mature mammalian astrocytes: a current view. Neuroscientist 2010;16:79-106.
145. Yang Y, et al. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia 2011;59:200-207.
146. Pfrieger FW, Slezak M. Genetic approaches to study glial cells in the rodent brain. Glia 2012;60:681-701.
147. Cahoy JD, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008;28:264-278.
148. Foo LC, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron 2011;71:799-811.
149. Saura J. Microglial cells in astroglial cultures: a cautionary note. J Neuroinflammation 2007;4:26.
150. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65:2702-2720.
151. Hinson SR, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012;109:1245-1250.
152. Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 2011;306:183-187.
153. Kang Z, et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010;32:414-425.
154. Levy H, Assaf Y, Frenkel D. Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol 2010;226:148-158.
155. Titeux M, Galou M, Gomes FCA, Dormont D, Neto VM, Paulin D. Differences in the activation of the GFAP gene promoter by prion and viral infections. Brain Res Mol Brain Res 2002;109:119-127.
156. Skripuletz T, et al. Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol 2010;20:301-312.
157. Bush TG, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999;23:297-308.
158. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004;24:2143-2155.
159. Voskuhl RR, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009;29:11511-11522.
160. Toft-Hansen H, Füchtbauer L, Owens T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia 2011;59:166-176.
161. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007;28:138-145.
162. Calderon TM, et al. A role for CXCL12 (SDF-1α) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 2006;177:27-39.
163. Alter A, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003;170:4497-4505.
164. Han Y, He T, Huang DR, Pardo CA, Ransohoff RM. TNF-α mediates SDF-1α-induced NF-κB activation and cytotoxic effects in primary astrocytes. J Clin Invest 2001;108:425-435.
165. Bajetto A, et al. Stromal cell-derived factor-1α induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway. J Neurochem 2001;77:1226-1236.
166. Patel JR, McCandless EE, Dorsey D, Klein RS. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc Natl Acad Sci USA 2010;107:11062-11067.
167. Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia 2005;50:258-269.
168. Banisadr G, et al. The role of CXCR4 signaling in the migration of transplanted oligodendrocyte progenitors into the cerebral white matter. Neurobiol Dis 2011;44:19-27.
169. Zhang K, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003;6:1064-1071.
170. Zeinstra E, Wilczak N, Streefland C, Keyser JD. Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules. NeuroReport 2000;11:89-91.
171. Kort JJ, Kawamura K, Fugger L, Weissert R, Forsthuber TG. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. J Neuroimmunol 2006;173:23-34.
172. Chastain EML, Duncan DS, Rodgers JM, Miller SD. The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta 2011;1812:265-274.
173. Lee SC, Moore GR, Golenwsky G, Raine CS. Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurol 1990;49:122-136.
174. Magnus T, Chan A, Linker RA, Toyka KV, Gold R. Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol 2002;61:760-766.
175. Aloisi F, Serafini B, Adorini L. Glia-T cell dialogue. J Neuroimmunol 2000;107:111-117.
176. Gimenez MAT, Sim JE, Russell JH. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol 2004;151:116-125.
177. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990;136:1309-1316.
178. Bechmann I, et al. Astrocyte-induced T cell elimination is CD95 ligand dependent. J Neuroimmunol 2002;132:60-65.
179. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999;27:62-74.
180. Pender MP, Nguyen KB, McCombe PA, Kerr JFR. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 1991;104:81-87.
181. Xiao BG, Xu LY, Yang JS, Huang YM, Link H. An alternative pathway of nitric oxide production by rat astrocytes requires specific antigen and T cell contact. Neurosci Lett 2000;283:53-56.
182. Hara H, Nanri Y, Tabata E, Mitsutake S, Tabira T. Identification of astrocyte-derived immune suppressor factor that induces apoptosis of autoreactive T cells. J Neuroimmunol 2011;233:135-146.
183. Didier N, Romero IA, Créminon C, Wijkhuisen A, Grassi J, Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003;86:246-254.
184. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004;10:290-297.
185. Mohan H, et al. Extracellular matrix in multiple sclerosis lesions: fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol 2010;20:966-975.
186. Cuzner ML, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204.
187. Gardner J, Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 2003;74:801-806.
188. Holley JE, Gveric D, Newcombe J, Cuzner ML, Gutowski NJ. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol 2003;29:434-444.
189. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009;32:638.
190. Göritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisén J. A pericyte origin of spinal cord scar tissue. Science 2011;333:238-242.
191. Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009;10:235-241.
192. Bannerman P, Hahn A, Soulika A, Gallo V, Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 2007;55:57-64.
193. Goddard DR, Berry M, Butt AM. In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system. J Neurosci Res 1999;57:74-85.
194. Clemente D, Ortega MC, Arenzana FJ, de Castro F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J Neurosci 2011;31:14899-14909.
195. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146-156.
196. Asher RA, et al. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci 2000;20:2427-2438.
197. Sobel RA, Ahmed AS. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J Neuropathol Exp Neurol 2001;60:1198-1207.
198. Haist V, Ulrich R, Kalkuhl A, Deschl U, Baumgärtner W. Distinct spatio-temporal extracellular matrix accumulation within demyelinated spinal cord lesions in Theiler's murine encephalomyelitis. Brain Pathol 2011;22:188-204.
199. Liu J-Q, et al. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol 2007;178:6227-6235.
200. Miljkovic D, Timotijević G, Stojković MM. Astrocytes in the tempest of multiple sclerosis. FEBS Lett 2011;585:3781-3788.
201. Trajkovic V, et al. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. Glia 2004;47:168-179.
202. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011;350:1-15.
203. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol 1998;160:4271-4279.
204. Miljkovic D, et al. Astrocytes stimulate interleukin-17 and interferon-gamma production in vitro. J Neurosci Res 2007;85:3598-3606.
205. Saikali P, Antel JP, Pittet CL, Newcombe J, Arbour N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J Immunol 2010;185:5693-5703.
206. Almolda B, González B, Castellano B. Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front Biosci 2011;16:1157-1171.
207. Zhou Y, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011;186:4415-4421.
208. Krumbholz M, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195-200.
209. Krumbholz M, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455-1463.
210. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004;152:183-190.
211. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 2009;9:132-135.
212. Kinoshita M, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010;394:205-210.
213. Aloisi F, Penna G, Cerase J, Menéndez Iglesias B, Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997;159:1604-1612.
214. Min K-J, Yang M-S, Kim S-U, Jou I, Joe E-H. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci 2006;26:1880-1887.
215. DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 1998;149:329-340.
216. Ambrosini E, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005;64:706-715.
217. Hao J, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010;207:1907-1921.
218. Moodley K, Angel CE, Glass M, Graham ES. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. J Neurosci Methods 2011;200:173-180.
219. Seeldrayers PA, Levin LA, Johnson D. Astrocytes support mast cell viability in vitro. J Neuroimmunol 1992;36:239-243.
220. Kim DY, Jeoung D, Ro JY. Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis. J Immunol 2010;185:273-283.
221. Kim D-Y, Hong GU, Ro JY. Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. J Neuroinflammation 2011;8:25.
222. Freedman MS, D'Souza S, Antel JP γδ T-cell-human glial cell interactions. I. In vitro induction of γδ T-cell expansion by human glial cells. J Neuroimmunol 1997;74:135-142.
223. Amor S, Smith PA, Hart BT, Baker D. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol 2005;165:1-10.
224. Herges K, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 2012;18:398-408.